Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
8Customers
3Debt Items
4Related Chains
Source-Backed Evidence Depth
CEL-SCI Corporation (CVM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
5Distinct source URLs
14High confidence
0.883Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CEL-SCI Corporation Suppliers
Ticker
Name
Confidence
Evidence
ERGOMED-GROUP-LIMITED
ERGOMED-GROUP-LIMITED
92%
In November 2025, the Company entered into a Securities Purchase Agreement with Ergomed Group Limited (“Ergomed”) pursuant to which the Company issued 375,000 shares of common stock in exchange for s…
GCP-CLINICAL-STUDIES-LTD
GCP-CLINICAL-STUDIES-LTD
80%
In January 2012, pursuant to an assignment and assumption agreement between CEL-SCI, Teva and GCP Clinical Studies Ltd., or GCP, Teva transferred all of its rights and obligations concerning the Phas…
Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive com…
CEL-SCI Corporation Customers
Ticker
Name
Confidence
Evidence
AMAROX
AMAROX
92%
the Company issued a press release, filed as Exhibit 99, concerning a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential co…
ERGOMED-GROUP-LIMITED
ERGOMED-GROUP-LIMITED
92%
During the six months ended March 31, 2026, 94,000 shares were sold by Ergomed and the proceeds were used to settle $ 144,
THINKEQUITY-LLC
THINKEQUITY-LLC
92%
On May 11, 2026, CEL-SCI Corporation...entered into a Placement Agency Agreement with ThinkEquity LLC (the “Placement Agent”) relating to the sale and issuance of 6,000,000 shares of the Company’s co…
BYRON-BIOPHARMA-LLC
BYRON-BIOPHARMA-LLC
90%
CEL-SCI has licensed future sales of Multikine, if approved, to Byron BioPharma, LLC in South Africa
DALLAH-PHARMA
DALLAH-PHARMA
90%
CEL-SCI is developing a commercialization and regulatory partnership agreement with Dallah for Multikine in the treatment of head and neck cancer in the Kingdom of Saudi Arabia.
ORIENT-EUROPHARMA-CO-LTD
ORIENT-EUROPHARMA-CO-LTD
90%
Pursuant to this agreement, as amended, Orient Europharma has the exclusive marketing and distribution rights to Multikine, if approved by regulatory authorities, for head and neck cancer, naso-phary…
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD
90%
CEL-SCI signed an agreement with Teva Pharmaceutical Industries Ltd., or Teva, that gives Teva the exclusive right and license to market, distribute and sell Multikine, if approved, in Israel and Tur…
PLIVA-HRVATSKA-D-O-O
PLIVA-HRVATSKA-D-O-O
85%
In July 2011, Serbia and Croatia were added to Teva's territory, pursuant to a joinder agreement between CEL-SCI and PLIVA Hrvatska d.o.o., or PLIVA, an affiliate of Teva's, subject to similar terms …
CEL-SCI Corporation Debt Obligations
Instrument
Description
Confidence
Evidence
CVM-DEBT
Debt stack $9.1M
90%
Market cache reports total debt of $9.1M.
CVM-DEBT-8956
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2024-09-30.
CVM-DEBT-8957
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-06-30.
CEL-SCI Corporation Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CEL-SCI Corporation.
CEL-SCI Corporation Ownership
Holder
Name
Confidence
Evidence
CVM-OWNER-FORTHRIGHT-FAMILY-WEALTH-ADVISOR
Forthright Family Wealth Advisory LLC
90%
13F overlay lists Forthright Family Wealth Advisory LLC as top holder; 2 tracked holders.
